TXG (10x Genomics) Total Stockholders Equity: $825.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TXG 10x Genomics Inc TXG
58 GF Score
Price $65.12
GF Value $18.37
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is 10x Genomics Total Stockholders Equity?

10x Genomics TXG +1.96% 58 Total Stockholders Equity is $825.5 Mil as of Jun. 2026. GuruFocus rates TXG with a GF Score™ of 58/100 and a GF Value™ of $18.37 (Significantly Overvalued). The stock has 8 warning signs investors should review.

10x Genomics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $825.5 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. 10x Genomics's Book Value per Share for the quarter that ended in Jun. 2026 was $6.34. The ratio of a company's debt over equity can be used to measure how leveraged this company is. 10x Genomics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.10.

10x Genomics  (NAS:TXG) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

10x Genomics's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(825.546-0)/130.282
=6.34

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

10x Genomics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(12.015 + 66.781) / 825.546
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics Total Stockholders Equity Related Terms

10x Genomics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for 10x Genomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics Total Stockholders Equity Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 817.57 805.74 741.04 710.13 796.33

10x Genomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 773.28 785.12 796.33 814.32 825.55
TXG
58GF Score
10x Genomics Inc TXG
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $825.5 Mil mean?
10x Genomics (TXG) has a Total Stockholders Equity of $825.5 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for 10x Genomics and its competitors.
Is 10x Genomics' Total Stockholders Equity too high?
10x Genomics' current Total Stockholders Equity is $825.5 Mil. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Total Stockholders Equity compare to HNGE and WAY?
10x Genomics' Total Stockholders Equity of $825.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Healthcare Providers & Services company?
A good Total Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for 10x Genomics and its competitors. 10x Genomics's current Total Stockholders Equity is $825.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.37, compared to a current price of $65.12 — trading 254.5% above its estimated fair value. The current Total Stockholders Equity is $825.5 Mil. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For 10x Genomics (TXG), the current Total Stockholders Equity is $825.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 10x Genomics (TXG) Overvalued in 2026?

Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued. The current stock price of $65.12 is trading 254.5% above its estimated GF Value™ of $18.37. GuruFocus considers 10x Genomics to be Significantly Overvalued.

Key valuation signals for TXG:

  • Total Stockholders Equity: $825.5 Mil
  • GF Value™: $18.37 vs. price of $65.12 (254.5% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

10x Genomics Business Description

Other Exchanges 0A88:UK1KJ:Germany
Address 6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score

Get the complete analysis for TXG

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.12
Price
$18.37
GF Value